Clinical Trial Update: Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial results for futibatinib plus pembrolizumab in advanced hepatocellular carcinoma (BCLC A-C and metastatic) have been completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Futibatinib (futibatinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Mayo Clinic | Conditions: Advanced Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2025-10-29